Zobrazeno 1 - 10
of 318
pro vyhledávání: ''
Publikováno v:
Cardiovascular Drugs and Therapy, 37(2), 283-289. Kluwer Academic Publishers
Purpose Hydralazine, doxazosin, and verapamil are currently recommended by the Endocrine Society as acceptable bridging treatment in those in whom full cessation of antihypertensive medication is infeasible during screening for primary aldosteronism
Autor:
Jiana Chen, Wenlin Xu, Jiafen Qian, Shuyi Wu, Mingrong Chen, Jinhua Zhang, Zongwei Fang, Meina Lv, Zhiwei Zeng, Shaojun Jiang
Publikováno v:
Cardiovascular Drugs and Therapy. 37:363-377
We aimed to determine the safety of direct oral anticoagulants (DOACs) for stroke prevention and treatment in patients with atrial fibrillation (AF). A systematic search of four databases (PubMed, EMBASE, Web of Science, and Cochrane Library) was per
Publikováno v:
Cardiovascular Drugs and Therapy. 36:829-840
Ticagrelor and dapagliflozin can suppress the activation of the NOD-like receptor 3 (NLRP3)-inflammasome and activate AMP-activated protein kinase (AMPK). The anti-inflammatory effects of dapagliflozin has been shown to depend on AMPK activation. Dap
Autor:
Asmaa M A Bayoumi, Sayed Shehata, Marwa M.M. Refaie, Walaa Yehia Abdelzaher, Nashwa Fathy Gamal El-Tahawy
Publikováno v:
Cardiovascular Drugs and Therapy. 36:817-827
The cardiotoxicity of anticancer drugs such as 5-fluorouracil (5FU) is a major complication that challenges their clinical usefulness. Thus there is a critical need to find new protective drugs to defend against these harmful side effects. Up to now,
Publikováno v:
Cardiovascular Drugs and Therapy. 36:777-792
Primarily used in the treatment of intermittent claudication, cilostazol is a 2-oxyquinolone derivative that works through the inhibition of phosphodiesterase III and related increases in cyclic adenosine monophosphate (cAMP) levels. However, cilosta
Autor:
Eue Keun Choi, Seil Oh, Jin Hyung Jung, Gregory Y.H. Lip, Soonil Kwon, Kyungdo Han, So Ryoung Lee
Publikováno v:
Lee, S R, Kwon, S, Choi, E K, Jung, J H, Han, K D, Oh, S & Lip, G Y H 2022, ' Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding ', Cardiovascular Drugs and Therapy, vol. 36, no. 4, pp. 679–689 . https://doi.org/10.1007/s10557-021-07170-6
Purpose: The risk of gastrointestinal bleeding (GIB) can be mitigated by proton pump inhibitor (PPI) co-therapy in patients with atrial fibrillation (AF) treated with anticoagulants. We aimed to evaluate the effect of PPIs on the risk of GIB in Asian
Publikováno v:
Cardiovascular Drugs and Therapy. 36:309-322
Between 2012 and 2017, the FDA approved 29 therapies for a cardiovascular disease (CVD) indication. Due to the limited literature on patient safety outcomes for recently approved CVD medications, this study investigated adverse drug reports (ADRs) re
Autor:
Changyuan Wang, Dalong Wang, Kexin Liu, Huijun Sun, Tingting Zhao, Jingjing Wu, Shan Zhao, Qiang Meng, Peipei Dong, Yanwei Chen, Liyan Wang
Publikováno v:
Cardiovascular Drugs and Therapy. 36:121-129
Rivaroxaban, an oral anticoagulant, undergoes the metabolism mediated by human cytochrome P450 (CYP). The present study is to quantitatively analyze and compare the contributions of multiple CYPs in the metabolism of rivaroxaban to provide new inform
Pharmacologic Cardioversion in Patients with Paroxysmal Atrial Fibrillation: A Network Meta-Analysis
Autor:
Konstantinos Gatzoulis, Ioannis Doundoulakis, Konstantinos Tsioufis, Athanasios Kordalis, Spyridon Deftereos, Christodoulos Stefanadis, Dimitris Tsiachris, Eirini Pagkalidou
Publikováno v:
Cardiovascular Drugs and Therapy. 35:293-308
We sought to indirectly compare and rank antiarrhythmic agents focusing exclusively on adults with paroxysmal atrial fibrillation in order to identify the most effective for pharmacologic cardioversion over different time settings (4 h as primary, an
Publikováno v:
Cardiovascular Drugs and Therapy. 36:103-112
Although the use of direct oral anticoagulants (DOACs) has been reported in patients with atrial fibrillation (AF), there is currently no consensus on the occurrence or characteristics of the hemorrhage risk in different antithrombotic regimens. Disp